New York’s cannabis market is expanding rapidly.
Following the legalisation of adult-use cannabis in 2021 and the launch of sales in 2022, the state is now one of the largest cannabis markets in the U.S. Legal cannabis sales are projected to exceed US$1.8 billion in 2025 and reach US$4.2 billion by 2029, driven primarily by the adult-use segment.

Medical cannabis participation is declining.
After peaking at over 150,000 registered patients in 2021, numbers are forecast to fall to around 83,000 by the end of 2025. Contributing factors include easier access to adult-use cannabis, high product costs, lack of insurance coverage, and competition from illicit products. A new Senate Bill (S3294A) aims to stabilise the framework by extending certifications to two years and allowing home cultivation.

Retail sales are breaking records.
In the first eight months of 2025 alone, retail cannabis sales surpassed $1.1 billion, marking a 28% year-on-year increase. August 2025 recorded a record $214 million in monthly sales, reflecting accelerating consumer adoption and a rapidly expanding retail footprint.

Product preferences are shifting.
As of September 2025, flower and pre-rolls accounted for 55.8% of sales, underscoring a preference for smokable products. However, vapes (25.4%) and edibles (13.1%) continue to gain market share as consumers explore alternative and healthier formats.

Licensing remains complex and unevenly distributed.
There are currently around 2,170 active cannabis licences across the state, with a further 375 pending. Geographic disparities persist, with New York City and Hudson Valley hosting the majority of retail operations. Legal and administrative challenges continue to delay market rollout and equity implementation.

Supply pressures and illicit competition persist.
Despite sufficient licensed capacity, 2025 cultivation yields are estimated to meet only 50% of 2026 demand, creating a gap likely filled by illicit out-of-state products. This undermines legal cultivators and contributes to ongoing enforcement issues, as highlighted by the October 2025 OCM action against Omnium.

Retailer sentiment is cautiously optimistic.
A Business of Cannabis x Prohibition Partners survey of 13 licensed retailers revealed high satisfaction with product quality (69.3%), availability (69.2%), and variety (84.6%), but persistent concerns over market saturation, heavy regulation, and limited financial services. Dried flower, pre-rolls, and vapes were cited as top sellers, while craft products and topicals were seen as underrepresented categories.